Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Clinical Breast Cancer|August 14, 2010
A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01)Sara A Hurvitz, Heather J Allen, Rebecca L Moroose, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2024
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5Javier Cortés, Sara A Hurvitz, Joyce O'Shaughnessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast CancerMatthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Nature Cancer|December 30, 2021
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts responseKatherine L McNamara, Jennifer L Caswell-Jin, Rohan Joshi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2013
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancerFabrice André, Thomas Bachelot, Mario Campone, et al.
Breast Cancer Research : BCR|August 16, 2020
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancerNeil A O'Brien, Martina S J McDermott, Dylan Conklin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2018
A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO)Nicholas C Turner, Melinda L Telli, Hope S Rugo, et al.
The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.
Breast Cancer Research and Treatment|May 11, 2022
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancerJoyce O'Shaughnessy, Adam Brufsky, Hope S Rugo, et al.
NPJ Breast Cancer|August 29, 2022
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancerHope S Rugo, Sara M Tolaney, Delphine Loirat, et al.
Pageof 14